Tumor News and Research

RSS

Understanding of tumor biology opens new opportunities to conduct clinical trial for thoracic tumors

Our understanding of tumor biology has improved and continues to expand at a rapid pace, and this has opened new opportunities for cancer clinical trials, particularly for thoracic tumors. The identification and molecular alterations in the cancer and the possibility to specifically and selectively target them, has dramatically improved the treatment efficacy in patients with lung cancer.

24 Jun 2015

Selective use of biomarker testing for breast cancer patients can save millions of dollars in health care spending

A review of medical records for almost 200 patients with breast cancer suggests that more selective use of biomarker testing for such patients has the potential to save millions of dollars in health care spending without compromising care, according to Johns Hopkins researchers.

23 Jun 2015

Dr. Maurizio D'Incalci to receive Pezcoller-Prodi Award in Scientific Career

Dr. Maurizio D'Incalci, MD, Ph.D., will receive an award in recognition of his scientific career at the new Special Conference on Anticancer Drug Action and Drug Resistance: from Cancer Biology to the Clinic organized by the European Association of Cancer Research, the American Association of Cancer Research and the Italian Cancer Society and that will be held in Florence, Italy, June 20-23.

23 Jun 2015

Statins benefit patients undergoing major lung resection, lower major complications

Statins have been shown to reduce complications from cardiovascular surgery. To determine whether statins might also help those undergoing major lung surgeries, a team at Memorial Sloan Kettering Cancer Center conducted a well-designed study that randomized patients to receive either a statin or placebo before and after surgery.

23 Jun 2015

Targeted molecular-imaging method could help identify early stages of prostate cancer

A targeted molecular-imaging method under development at Rochester Institute of Technology could help detect early stages of prostate cancer and improve image-directed biopsies.

23 Jun 2015

PSMA can be an ideal target for diagnosis and treatment of prostate cancer

Prostate-specific membrane antigen (PSMA) is a surface protein that is normally present on healthy prostate cells, but is found at much higher levels on prostate cancer cells. It is barely found in the rest of the body. "Therefore, PSMA is an ideal target for diagnostic purposes as well as targeted therapies against prostate cancer," says biotechnologist Dr. Matthias Eder of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ).

23 Jun 2015

3SBio obtains ex-China global rights to Apexigen's anti-TNF mAb technology

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the ex-China global rights to Apexigen's anti-TNF monoclonal antibody ("mAb") technology. 3SBio previously acquired the China rights from Apexigen in 2006.

23 Jun 2015

Vaxon Biotech receives new patent in Japan for cancer vaccine candidates

Vaxon Biotech, a company specialized in anti-tumor immunotherapy, today announces that it has been granted a new patent in Japan. This patent covers a series of optimized cryptic peptides to be used in the design of the Vbx-026, a new cancer vaccine for solid tumors.

22 Jun 2015

VG Life Sciences receives U.S. patent for combination cancer therapy

VG Life Sciences, Inc., a biotechnology company developing therapies for cancer, autoimmune and infectious diseases, announced that the U.S. Patent and Trademark Office will issue Patent No. 9073985 covering VGLS' combination therapy for treating drug-resistant cancer by combining an autophagy inhibitor with a chemotherapy drug.

22 Jun 2015

Vaxil's ImMucin receives FDA orphan drug designation for treatment of multiple myeloma

Vaxil Bio, a company specializing in the development of immunotherapy-based drugs, reports today that its lead product, ImMucin, has been granted an "orphan drug" designation by the US Food and Drug Administration, for the treatment of multiple myeloma (MM).

22 Jun 2015

ImmunoCellular, Pure MHC partner to develop new assay for ICT-107 phase 3 registrational clinical program

ImmunoCellular Therapeutics, Ltd. announced an agreement with Pure MHC, an Emergent Technologies portfolio company, for development of a novel assay for quality control that will be an important component of ImmunoCellular's ICT-107 phase 3 registrational clinical program in newly diagnosed glioblastoma, anticipated to begin in the second half of 2015.

22 Jun 2015

Researchers use different approaches to test ways to manipulate nanoparticles in medicine

Nanoparticles are the smallest particles capable of reaching virtually all parts of the body. Researchers use various approaches to test ways in which nanoparticles could be used in medicine - for instance, to deliver substances to a specific site in the body such as a tumor.

22 Jun 2015

Hormones used in breast cancer treatment could affect disease progression, outcomes in some patients

Recently, researchers have discovered that the hormone progesterone, an ingredient in contraceptives and menopausal hormone replacement therapies, might stimulate the growth of breast cancer cells that are resistant to anti-estrogen therapy and chemotherapy.

22 Jun 2015

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Eli Lilly and Company announced that The Lancet Oncology has published results of the Phase III REACH trial that evaluated CYRAMZA (ramucirumab) as a second-line treatment for people with hepatocellular carcinoma (HCC), also known as liver cancer. While the REACH trial's primary endpoint of overall survival favored the CYRAMZA arm, it was not statistically significant.

19 Jun 2015

UNC Lineberger scientists contribute to better understanding of genetic mutations in melanoma

UNC Lineberger Comprehensive Cancer Center researchers have significantly contributed to a better understanding of the genetic alterations found in cutaneous melanoma, the most lethal form of skin cancer, as part of a multi-institution, international effort of The Cancer Genome Atlas.

19 Jun 2015

Scientists identify four melanoma subtypes that share common 'downstream' signaling pathways

Cutaneous melanoma, the most deadly form of skin cancer, is now believed to be divided into four distinct genomic subtypes, say researchers at The University of Texas MD Anderson Cancer Center, a finding that could prove valuable in the ever-increasing pursuit of personalized medicine.

19 Jun 2015

New technology offers advanced detection in drug and other healthcare screenings

A George Washington University professor has designed new technology that can identify traces of chemicals at 10-19 moles, a previously undetectable amount. This minute quantity can be conceptualized as 10 times below a billionth of a billionth of a teaspoon of water.

19 Jun 2015

Mayo Clinic, TGen researchers help launch national clinical trial to treat advanced skin cancer patients

Mayo Clinic and the Translational Genomics Research Institute are helping launch a national clinical trial that will apply the latest in precision medicine to treat advanced melanoma skin cancer.

19 Jun 2015

Researchers explore the science of exosomes in heart repair

A little more than a decade ago, researchers discovered that all cells secrete tiny communications modules jammed with an entire work crew of messages for other cells. Today, a team of researchers, led by stem cell researcher Raj Kishore, PhD, Director of the Stem Cell Therapy Program at the Center for Translational Medicine at Temple University School of Medicine, is harnessing the communications vesicles excreted by stem cells and using them to induce the damaged heart to repair itself.

19 Jun 2015

Study suggests that blood clots in abdominal vein could be an indicator of undiagnosed cancer

New research published online today in Blood, the Journal of the American Society of Hematology (ASH), concludes that a blood clot in an abdominal vein may be an indicator of undiagnosed cancer. The study also suggests that these clots predict poorer survival in patients with liver and pancreatic cancer.

19 Jun 2015

Tumor News and Research

Understanding of tumor biology opens new opportunities to conduct clinical trial for thoracic tumors

Selective use of biomarker testing for breast cancer patients can save millions of dollars in health care spending

Dr. Maurizio D'Incalci to receive Pezcoller-Prodi Award in Scientific Career

Statins benefit patients undergoing major lung resection, lower major complications

Targeted molecular-imaging method could help identify early stages of prostate cancer

PSMA can be an ideal target for diagnosis and treatment of prostate cancer

3SBio obtains ex-China global rights to Apexigen's anti-TNF mAb technology

Vaxon Biotech receives new patent in Japan for cancer vaccine candidates

VG Life Sciences receives U.S. patent for combination cancer therapy

Vaxil's ImMucin receives FDA orphan drug designation for treatment of multiple myeloma

ImmunoCellular, Pure MHC partner to develop new assay for ICT-107 phase 3 registrational clinical program

Researchers use different approaches to test ways to manipulate nanoparticles in medicine

Hormones used in breast cancer treatment could affect disease progression, outcomes in some patients

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

UNC Lineberger scientists contribute to better understanding of genetic mutations in melanoma

Scientists identify four melanoma subtypes that share common 'downstream' signaling pathways

New technology offers advanced detection in drug and other healthcare screenings

Mayo Clinic, TGen researchers help launch national clinical trial to treat advanced skin cancer patients

Researchers explore the science of exosomes in heart repair

Study suggests that blood clots in abdominal vein could be an indicator of undiagnosed cancer

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News